Neuland Laboratories

Neuland Laboratories Forward P/E

The Forward P/E Ratio of Neuland Laboratories (NEULANDLAB.NS) as of Oct 29, 2026 is 43.73. In the previous year, Forward P/E Ratio was 61.20 — a change of -28.54% (lower).

Forward P/E

43.73

YoY

-28.54%

Last updated:

Forward P/E Ratio of Neuland Laboratories is 2026 43.73 . Forward P/E Ratio of Neuland Laboratories was 2025 61.20 . It decreases by -28.54% lower compared to the previous year.

The Neuland Laboratories Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
968.20 INR
Jan 1, 2020
982.01 INR
Jan 1, 2021
197.43 INR
Jan 1, 2022
249.43 INR
Jan 1, 2023
97.35 INR
Jan 1, 2024
53.05 INR
Jan 1, 2025
61.20 INR
Jan 1, 2026
43.73 INR
The Neuland Laboratories Forward P/E history
YEARForward P/EYoY
43.73-28.54%
61.20+15.37%
53.05-45.51%
97.35-60.97%
249.43+26.34%
197.43-79.90%
982.01+1.43%
968.20-26.63%
1,319.65+288.50%
339.68-41.69%
582.58-41.64%
998.24+68.10%
593.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Forward P/E Ratio of Neuland Laboratories is 43.73 in 2026.

Forward P/E Ratio of Neuland Laboratories changed from 61.20 to 43.73, representing a -28.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuland Laboratories

All Key Metrics — Neuland Laboratories